Chairman: Peter Collins, Vice Président Diagnostics GSK and Board member of EPEMED
Vice Chair: Patrick Korman, Myriad Genetics SAS, Europe Vice President, Economics, Public Affairs & BD and EPEMED Member
Vice Chair: Juliette Plun-Favreau, Genomic Health, Director Reimbursement & Market Access and EPEMED Member
The personalised medicine field has made great advances. It has become a strategic activity within many organisations with significant investments made by large and small businesses worldwide. Consequently, the focus of issues around personalised medicine has shifted from being a hypothetical to the real challenges of implementation of diagnostics and related therapies. Europe presents some very unique challenges for market access, evidence review, coverage, and payment.
EPEMED has become the lead organisation in Europe focused on advancing personalised medicine. We have concentrated our efforts on informing and educating a variety of parties through the creation of educational events. Furthermore, EPEMED has prepared a number of white papers on market access challenges, which are in press.
During 2013, EPEMED will continue to grow the organisation to permit more interaction with a broader set with European policy makers and regulators and payers to facilitate awareness and support by decision makers for market access to personalised medicine products across Europe.
Personalised medicine requires a new mode of thinking with major impacts on how drugs and diagnostics are evaluated, valued and reimbursed. There is a need for multi - stakeholder discussions of HTA, Health Economics, Regulators and Payers allied to treating physicians, Pathologists, diagnosticians and patients.
In this context, the Health Economic Policy and Reimbursement committee of EPEMED should focus on the following:
For more details, please contact Peter Collins at PETER.X.COLLINS (at) GSKBIO.COM